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Abstract: Burkholderia cepacia complex (BCC) bacteria are a group of opportunistic pathogens that
cause severe lung infections in cystic fibrosis (CF). Treatment of BCC infections is difficult, due to the
inherent and acquired multidrug resistance of BCC. There is a pressing need to find new bacterial
targets for antimicrobials. Here, we demonstrate that the novel compound Q22, which is related to the
bacterial cytoskeleton destabilising compound A22, can reduce the growth rate and inhibit growth of
BCC bacteria. We further analysed the phenotypic effects of Q22 treatment on BCC virulence traits,
to assess its feasibility as an antimicrobial. BCC bacteria were grown in the presence of Q22 with a
broad phenotypic analysis, including resistance to H2O2-induced oxidative stress, changes in the
inflammatory potential of cell surface components, and in-vivo drug toxicity studies. The influence
of the Q22 treatment on inflammatory potential was measured by monitoring the cytokine responses
of BCC whole cell lysates, purified lipopolysaccharide, and purified peptidoglycan extracted from
bacterial cultures grown in the presence or absence of Q22 in differentiated THP-1 cells. BCC bacteria
grown in the presence of Q22 displayed varying levels of resistance to H2O2-induced oxidative
stress, with some strains showing increased resistance after treatment. There was strain-to-strain
variation in the pro-inflammatory ability of bacterial lysates to elicit TNFα and IL-1β from human
myeloid cells. Despite minimal toxicity previously shown in vitro with primary CF cell lines, in-vivo
studies demonstrated Q22 toxicity in both zebrafish and mouse infection models. In summary,
destabilisation of the bacterial cytoskeleton in BCC, using compounds such as Q22, led to increased
virulence-related traits in vitro. These changes appear to vary depending on strain and BCC species.
Future development of antimicrobials targeting the BCC bacterial cytoskeleton may be hampered if
such effects translate into the in-vivo environment of the CF infection.
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1. Introduction
The Burkholderia cepacia complex (BCC) constitutes a group of over 20 closely related opportunistic
respiratory pathogen species associated with life-threatening infections in cystic fibrosis (CF) and
other immunocompromised patients. Of these species, B. cenocepacia and B. multivorans are the most
prevalent causes of infections in CF patients, and some strains have proved to be highly transmissible
between CF patients. BCC infections may remain established for many months, or even years, with
clinical outcomes highly variable and unpredictable; in some cases, they can lead to a severe and
often fatal complication known as “cepacia syndrome”. Cepacia syndrome is characterised by a
rapid clinical decline, with high fevers and bacteraemia, progressing to severe pneumonia and death;
its existence has led to BCC bacteria emerging as important respiratory pathogens within the CF
community. Their intrinsic and acquired resistance to most clinically relevant antimicrobials makes
BCC infections notoriously difficult to eradicate or manage. Understandably, due to concerns over
this multidrug resistance in BCC and other respiratory pathogens, such as Pseudomonas aeruginosa,
the development of new and novel antimicrobials is urgently required.
The majority of clinically available antibiotics generally target synthetic pathways, such as
DNA synthesis, protein synthesis, and RNA synthesis (reviewed in [1]), suggesting that there is
a need to identify new bacterial therapeutic targets that have an important cellular function or role.
A number of groups have revealed the presence of the bacterial cytoskeleton, and its potential as
an antimicrobial target has been recognized [2]. One cytoskeletal protein of particular interest is the
widely conserved actin homolog, MreB. This plays a role in a number of cellular functions, including
maintaining cell shape in rod-like bacteria. More recently the role of MreB has been found to be
associated with cell-surface-located virulence factors, further emphasizing the suitability of this protein
as an antimicrobial target. In the case of P. aeruginosa, MreB is required for motility and cell surface
localisation of the type IV pilus, a cell surface adhesin important for adhesion to mammalian cells
during infection and biofilm formation [3]. Additionally, Bulmer and colleagues have demonstrated
the MreB-associated cytoskeletal protein MreC is required for expression of Salmonella Typhimurium
type three secretion system-1 (T3SS-1) and flagella complexes, both important pathogenicity factors
required for colonisation and invasion of the intestine in vivo [4].
To date, few inhibitors of MreB have been identified. S-(3,4-dichlorobenzyl) isothiourea
hydrochloride (A22) is a small molecule inhibitor of MreB, originally identified as an inhibitor of
replication in E. coli [5]. A22 has an antimicrobial effect on a range of Gram-negative bacteria; however,
very little is known about the effects of A22 on virulence factor expression. Studies of Shigella flexneri
have shown that exposure to sub-MIC levels of A22 can reduce its ability to invade CHO-K1 cells
in vitro [6]. A further inhibitor of MreB, CBR-4830, was identified via a whole-cell antibacterial screen
for growth inhibitors of efflux-compromised P. aeruginosa strains [7]. CBR-4830 is a novel indole MreB
inhibitor chemically distinct from A22.
Recently, we assessed the antimicrobial activity of a panel of A22-related isothiourea hydrochloride
derivatives against multi-drug resistant clinical isolates of P. aeruginosa and BCC [8]. Here, we extend
the use of the lead candidate from this panel, S-(4-chlorobenzyl) isothiourea hydrochloride, named
Q22, a putative MreB inhibitor (also described as C2 by Nicholson et al.), and study the effects of
this compound on virulence-related traits of BCC bacteria [8]. We show that sub-lethal treatment
of BCC with Q22 altered virulence phenotypes, including increased resistance to oxidative stress
and pro-inflammatory potential, suggesting caution should be taken when targeting the bacterial
cytoskeleton of BCC for antimicrobial development.
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2. Results
2.1. Q22 Treatment Alters Cell Morphology, Reduces Growth Rate, and Inhibits Growth of
B. cenocepacia Species
Having recently established the antimicrobial activity of both A22 and Q22 against a panel of
BCC strains [8], we wanted to further analyse the effect of Q22 on growth and morphology of a
panel of BCC bacteria (Table 1). Initially we used B. cenocepacia J2315 as a test organism to determine
appropriate growth permissive levels of Q22 (Figure 1A). B. cenocepacia J2315 is a clinical ET-12
epidemic strain isolated from a CF patient [9]. Q22-treated B. cenocepacia J2315 cultures showed a
reduction in growth rate in a concentration-dependent manner (Figure 1A; 0 µg/mL vs. 40 µg/mL
Q22; p ≤ 0.05)). Based on these results, 30 µg/mL Q22 was selected as an appropriate, sub-lethal,
growth-permissive concentration for subsequent experiments. Upon exposure to 30 µg/mL Q22, all
BCC strains tested, including those listed in Table 1, demonstrated a reduction in growth rate (as
previously [8]). The degree of growth rate reduction varied between strains, and a lesser reduction
was observed upon exposure to Q22 when compared to A22. Changes in cell morphology from rod to
cocci forms were confirmed by scanning electron microscopy, supporting disruption of the MreB-based
cytoskeleton (Figure 1B).
Table 1. Bacterial strains used in this study.
Species Description Source
B. cenocepacia LMG16656 (J2315) Clinical isolate, CF patient, ET-12 epidemic strain BCCM
B. cenocepacia LMG18829 Clinical isolate, CF patient, epidemic strain BCCM
B. multivorans LMG13010 Clinical isolate, CF patient BCCM
B. vietnamiensis LMG16232 Clinical isolate, CF patient BCCM
BCCM, Belgian Coordinated Collection of Micro-organisms.
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Figure 1. Growth and morphological changes induced by Q22 treatment. (A) Growth of B. cenocepacia 
J2315 in the absence or presence of increasing concentrations of Q22 (0, 20, 30, 40 μg/mL); (B) scanning 
electron microscope images of B. cenocepacia J2315, untreated and after treatment with 30 μg/mL Q22 
at 6 h timepoint. 
2.2. Q22 Treatment Alters Ability of B. cenocepacia to Resist H2O2-Induced Oxidative Stress 
BCC bacteria are exposed to reactive oxygen species (ROS) during colonisation and infection of 
the CF lung, and have a number of strategies to combat this form of stress [10,11]. We evaluated the 
susceptibility of Q22-treated and untreated BCC cultures to H2O2 (Figure 2). The reduction in viability 
upon H2O2 exposure varied between BCC strains when grown without drug treatment, with B. 
cenocepacia strains LMG18829 and J2315 showing the greatest resistance at 20 mM H2O2 (Figure 2B,C). 
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2.2. 22 Treat ent Alters Ability of B. cenocepacia to Resist 2 2-Induced xidative Stress
BCC bacteria are exposed to reactive oxygen species (ROS) during colonisation and infection
of the CF lung, and have a number of strategies to combat this form of stress [10,11]. We evaluated
the susceptibility of Q22-treated and untreated BCC cultures to H2O2 (Figure 2). The reduction in
viability upon H2O2 exposure varied between BCC strains when grown without drug treatment,
with B. cenocepacia strains LMG18829 and J2315 showing the greatest resistance at 20 mM H2O2
(Figure 2B,C).
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Figure 2. Survival of B. cepacia complex (BCC) strains exposed to H2O2 in vitro. Late-stationary-phase 
cells were treated with varying concentrations of H2O2, 0 mM (A), 10 mM (B), and 20 mM (C), as 
described under Materials and Methods. Samples were plated in triplicate for colony counts, and 
percentage survival (expressed as % viability) was calculated relative to colony counts of untreated 
bacteria. * p < 0.05. Isolates included B. cenocepacia LMG16656 (J2315), B. cenocepacia LMG18829, B. 
multivorans LMG13010, and B. vietnamiensis LMG16232 (see Table 1). 
When compared to untreated controls, we observed an increase in H2O2 resistance for strain 
J2315 that was statistically significant (Figure 2C, p < 0.05). 
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We analysed the crude LPS profiles of WCLs prepared from BCC cultures exposed to Q22, to 
determine if this compound alters LPS composition when compared to untreated WCLs. WCLs were 
prepared from BCC strains grown in the presence and absence of 30 μg/mL Q22. Of the four strains 
tested, no significant differences in the LPS electrophoretic profile were observed. J2315 showed no 
difference in profile at all. To further assess if there were any changes in LPS structure, LPS was 
isolated from Q22-treated and untreated cultures of B. cenocepacia LMG18829, and lipid A extracted 
and analysed further by MALDI-TOF mass spectrometry (Table 2). Both LPS and lipid A showed a 
mixture of differently-acylated species, both carrying Ara4N residues on the polar heads. 
Interestingly, the Q22-treated LMG18829 strain also carried an unsubstituted tetra-acylated lipid A 
species, absent in the untreated strain (Table 2). However, no other significant differences in LPS 
structure were observed. 
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 B. cenocepacia LMG18829 Untreated B. cenocepacia LMG18829  
+30 µg/mL Q22 
Lipid A Species Intensity (%) Mass Intensity (%) Mass 
tetra-acylated lipid A   58.8 1444.9 
tetra-acylated lipid A + Ara4N 100 1576.4 100 1576.1 
tetra-acylated lipid A + 2 Ara4N 87.8 1707.5 60 1707.0 
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Negative ion MALDI-TOF spectrum analysis of lipid A isolated from B. cenocepacia LMG18829, grown 
in the presence and absence of 30 μg/mL Q22. 
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cells were treated with varying concentrations of H2O2, 0 ( ), 10 m (B), and 20 mM (C), as
described under Section 4. Samples were plated in triplicate for colony counts, and percentage survival
(expr ssed a % vi bility) was calculated relative to colony counts of untreated bacteria. * p < 0.05.
Isolat s included B. cen cepacia LMG16656 (J2315), B. cenocepacia LMG 8829, B. multivor ns LMG13010,
and B. viet amiensis LMG16232 (s e Tabl 1).
When compared to untreated controls, we observed an increase in H2O2 resistance for strain
J2315 that was statistically significant (Figure 2C, p < 0.05).
2.3. Q2 Treatment Does Not Alter Lipopolysac haride Profile of B. cenocepacia Strains
We analysed the crude LPS profiles of WCLs prepared from BCC cultures exposed to Q2 , to
determine if this compound alters LPS composition when compared to untreated WCLs. WCLs were
prepared from BC strains grown in the presence and absence of 30 µg/mL Q2 . Of the four strains
tested, no sig ifica t electrophoretic profile were observed. J2315 showed
no diff rence in profile at all. To further a se s if there i L S structure, LPS was
isolated from Q22-treated and untreated cult res of B. cenocepa ia LMG18829, and lipid A extracted and
analysed further by MALDI-TOF mass spectrom try (Table 2). Both LPS and lipid A showed a mixture
of differently-acylated spe ies, both carrying Ara4N esidues on the polar heads. Interestingly, the
Q22-treated LMG188 9 strain also carried an unsubstituted tetr -acylated lipid A species, abs nt in the
untreated strain (Tabl 2). However, no other significant differences in LPS structure w ob erved.
Table 2. Structural analysis of B. cenocepacia LMG18829 lipid A.
B. cenocepacia LMG18829 Untreated B. cenocepaciaLMG18829 + 30 µg/mL Q22
Lipid A Species Intensity (%) Mass Intensity (%) Mass
tetra-acylated lipid A 58.8 1444.9
tetra-acylated lipid A + Ara4N 100 1576.4 100 1576.1
tetra-acylated lipid A + 2 Ara4N 87.8 1707.5 60 1707.0
penta-acylated lipid A + Ara4N 48.7 1800.9 38.2 1801.0
penta-acylated lipid A + 2 Ara4N 39 1934.0 29 1932.2
Negative ion MALDI-TOF spectrum analysis of lipid A isolated from B. cenocepacia LMG18829, grown in the
presence and absence of 30 µg/mL Q22.
2.4. Q22 Treatment Alters Proinflammatory Potential of BCC Strains
BCC LPS has potent e dotoxic activity and can elicit high levels of pro-inflammatory
cytokines [12,13]. To determine if chemical disruption of the bacterial cytoskeleton using compound
Q22 alters the endotoxic potential of the bacteria, we stimulated differentiated THP-1 cells with WCLs,
known to be rich in LPS, prepared from cultures exposed to Q22. Pro-inflammatory cytokine responses
characteristic of those encountered within the host during BCC infection (TNFα and IL-1β) were
measured. Data demonstrated a variable strain-dependent increase in cytokine induction when cells
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were stimulated with lysates obtained from bacteria exposed to Q22, compared to those obtained
from untreated bacteria. This significant strain-specific increase was noted for both TNFα (Figure 3A;
p < 0.01) and IL-1β (Figure 3B; p < 0.05) responses for Q22-treated B. cenocepacia strain J2315, as well as
for TNFα (Figure 3A; p < 0.01) for Q22-treated B. cenocepacia strain LMG18829.
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To determine whether this strain-specific increase in pro-inflammatory response was
LPS-dependent, we pre-incubated THP-1 cells with a CD14 antibody prior to stimulation, to block
the TLR4-dependent stimulatory pathway used by LPS. The increased TNFα response observed with
B. cenocepacia J2315 Q22-treated lysates was not abolished with the CD14 antibody treatment, suggesting
the increased cytokine release was not LPS-driven (Figure 3C). This was further confirmed by observing
the TNFα response of THP-1 cells, stimulated with purified LPS extracted from B. cenocepacia J2315
cultures grown in the presence and absence of Q22. Results demonstrated no significant difference
in TNFα response, obtained by stimulation with B. cenocepacia J2315 LPS purified from treated and
untreated cultures (Figure 3C). This is in agreement with our finding that the LPS profile of B. cenocepacia
J2315 was not changed after Q22 treatment.
Peptidoglycan (PG) is a significant structural and immune-stimulatory component of the bacterial
cell wall, and could plausibly be affected by cytoskeletal disruption. To determine if the observed
increase in pro-inflammatory potential of the B. cenocepacia WCLs could be attributed to PG, we isolated
PG from two different BCC species, B. cenocepacia J2315 and B. multivorans LMG13010, each grown
in the presence and absence of 30 µg/mL Q22. The purified PG was subsequently used to stimulate
THP-1 cells, and TNFα responses were measured. Both BCC strains tested showed an increase in TNFα
production when the bacteria were exposed to 30 µg/mL Q22 prior to PG extraction, when compared
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to untreated controls; however, only the increase between the treated and untreated B. cenocepacia J2315
samples was statistically significant (p < 0.05) (Figure 3D).
2.5. Q22 Toxicity In-Vivo Studies in Zebrafish and Mouse Models
Preliminary experiments demonstrated negligible toxicity in THP-1 cells or CF primary bronchial
epithelial cells (data not shown) [14].
Ultimately, the potential for in-vivo toxicity must be considered when developing a compound for
antimicrobial use; therefore, we aimed to determine the effects of Q22 in vivo, utilising the zebrafish
embryo BCC infection model established by Vergunst and colleagues [15], and the BCC mouse lung
infection model optimised by Bragonzi and co-workers [16]. We aimed to extend the in vivo toxicity
testing in these models prior to Q22 infection protection assessment.
Zebrafish embryos, 30 h post-fertilisation, were incubated in different concentrations of Q22 in
embryo water. Whereas 100% of untreated control embryos and embryos incubated in 6.4 µg/mL
Q22 survived during a five-day observation period, a dose-dependent killing was observed with
higher doses of Q22 than were anticipated to be needed for antimicrobial effects (Figure 4; p < 0.0001).
A concentration of 64 µg/mL was lethal for the embryos on day five, but embryos started to die on
day three when incubated in embryo water with 640 µg/mL, a concentration that killed most of the
embryos on day four of the treatment. These results clearly indicate the toxicity of the compound
for zebrafish larvae, even at concentrations that are close to the appropriate bacterial, sub-lethal,
growth-permissive concentration of 30 µg/mL.
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demonstrated reduced mobility when compared with control mice during the first two days of 
treatment, and lungs showed signs of inflammation and damage macroscopically after four days. All 
control mice were healthy after treatment (Group 4). Based on these results suggesting significant 
pulmonary toxicity, and in the interests of animal welfare, no further in-vivo experiments were 
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Table 3. Toxicity of Q22 in the mouse model. 
Group 
Dose Q22 
(mg/kg) Results 
1 100 Mice died immediately after intra-tracheal administration of Q22 
2 50 Mice died immediately after intra-tracheal administration of Q22 
3 25 Mice showed reduced mobility compared with controls during first 2 
days after treatment. Lungs were inflamed and damaged after 4 days 
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Mice were injected IT with increasing concentrations of Q22 (25 mg/kg; 50 mg/kg; 100 mg/kg) and 
monitored for up to 4 days post administration. 
Figure 4. Toxicity of Q22 in the zebrafish embryo model. Zebrafish embryos were exposed to increasing
concentrations of Q22 (6.4 µg/mL; 64 µg/mL; 640 µg/mL) at 30 high power field and monitored for
survival for up to 120 h post-incubation. Data expressed as percentage survival.
Results of the preliminary toxicity study in mice demonstrated that mice exposed to higher
doses of Q22 100 mg/kg (Group 1) and 50 mg/kg (Group 2) after IT administration of Q22 were
moribund (could not right themselves after being placed in lateral recumbence), and thus were killed
and the experiment terminated (Table 3). Those mice exposed to the lower dose, 25 mg/kg Q22
(Group 3), demonstrated reduced mobility when compared with control mice during the first two
days of treatment, and lungs showed signs of inflammation and damage macroscopically after four
days. All control mice were healthy after treatment (Group 4). Based on these results suggesting
significant pulmonary toxicity, and in the interests of animal welfare, no further in-vivo experiments
were performed.
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Table 3. Toxicity of Q22 in the mouse model.
Group Dose Q22 (mg/kg) Results
1 100 Mice died immediately after intra-tracheal administration of Q22
2 50 Mice died immediately after intra-tracheal administration of Q22
3 25 Mice showed reduced mobility compared with controls during first2 days after treatment. Lungs were inflamed and damaged after 4 days
4 0 Mice were healthy after treatment
Mice were injected IT with increasing concentrations of Q22 (25 mg/kg; 50 mg/kg; 100 mg/kg) and monitored for
up to 4 days post administration.
3. Discussion
Although the emergence of drug-resistant bacteria is a pressing issue, there are few antimicrobials
in development for the treatment of infections caused by these organisms [17]. We assessed the
bacterial cytoskeleton as a potential novel antimicrobial target, using the highly antibiotic-resistant
BCC as a model group of organisms. To target the bacterial cytoskeleton, we tested the A22-related
compound S-(4-chlorobenzyl) isothiourea hydrochloride (named Q22 in this study) as a potential
antimicrobial candidate, and measured phenotypic changes in the virulence traits of BCC. In addition
to the expected changes in growth and morphology observed with other Gram-negative bacterial
species [4,18,19], we also observed unexpected increases in resistance to H2O2-induced oxidative
stress and the pro-inflammatory potential of Q22 treatment in selected strains. BCC strains are known
to show a heterogeneity with other phenotypes, even across apparently clonal isolates [20]. Hence,
the variation herein appears consistent with these prior data.
We are unable to provide a mechanistic explanation for this increased resistance to H2O2-induced
stress in strain J2315. It is possible that the physiological changes in cell shape and structure may alter
the release or access to oxidative stress-related enzymes, such as catalases, which may vary between
strains. The concept of a drug treatment providing an opportunistic pathogen with the increased
capacity to combat ROS is a concern. This is highly relevant, as protection against ROS, such as
hydrogen peroxide, is important for the survival of BCC persister cells [21]. Persister cells are cells that
have entered a dormant, multidrug-tolerant state, and are thought to play a role in the recalcitrance of
biofilm-related infections in vivo.
Furthermore, in-vitro data generated during this study has suggested that Q22 treatment can
increase the pro-inflammatory potential of certain BCC. As Q22 has been shown to depolymerise MreB
in other Gram-negative organisms [22], it is possible that by depolymerising the bacterial cytoskeleton
of BCC, Q22 may alter the structure of important bacterial pathogen-associated molecular patterns
(PAMPs) located within the cell wall. Our data suggests that Q22 does not significantly affect the
structure of the LPS component of the outer membrane, but may have an effect on the PG component.
To confirm a role for PG in the changes in cytokine response of Q22-treated strains, we are currently
investigating the structure of PG extracted from Q22-treated bacteria.
Recently, Q22 has been described as a breakdown product of an antibacterial compound,
MAC13243, found to inhibit the bacterial lipoprotein targeting chaperone LolA, identified during a
chemical genome screen [23]. Saturation transfer difference (STD) NMR analysis revealed that Q22
directly interacts with LolA in vitro. Therefore, we must consider that potential interactions of Q22
with LolA may contribute to the phenotypic changes seen here.
In conclusion, we have shown that sub-inhibitory concentrations of Q22 can alter and affect
the phenotypic traits of certain BCC. Importantly, in contrast to earlier studies performed in vitro
(unpublished data), our studies demonstrate that Q22 is highly toxic for zebrafish larvae and mice,
which suggest that this compound is an unacceptable candidate for drug development for the treatment
of human disease.
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Furthermore, as destabilisation of the bacterial cytoskeleton using compounds such as Q22 can
lead to unexpected increases of in-vitro, virulence-related traits, we believe future development of
antimicrobials targeting the BCC bacterial cytoskeleton may be hampered if such effects translate into
the in-vivo environment of CF infection, and consider that caution must be taken. Future studies that
study a wider panel of isolates may help understand how widespread our observations are across the
BCC. Further studies to help our understanding of the mechanistic basis of this increased virulence are
imperative for developing alternative control strategies.
4. Materials and Methods
4.1. Ethics Statement
Mammalian studies were conducted according to protocols approved by the San Raffaele Scientific
Institute (Milan, Italy) Institutional Animal Care and Use Committee (IACUC), and adhered strictly
to the Italian Ministry of Health guidelines for the use and care of experimental animals. Zebrafish
(Danio rerio) were kept and handled in compliance with the guidelines of the European Union for
handling laboratory animals (http://ec.europa.eu/environment/chemicals/lab_animals/home_en.
htm). Studies performed at VBMI are approved by the Direction Départementale de la Protection
des Populations (DDPP) du Gard (ID 30-189-4). The experiments were terminated before the larvae
reached the free feeding stage and did not classify as animal experiments according to the 2010/63/EU
Directive. Approval date: 1 October 2014.
4.2. Bacterial Strains and Growth Conditions
The bacterial strains used in this study are included in the international BCC reference panel [20]
and are described in Table 1. BCC strains were grown at 37 ◦C in Luria-Bertani (LB) broth,
unless otherwise indicated. Q22, kindly provided by Prof. John Perry [8], was maintained in
methanol at 1 mg/mL and stored at −20 ◦C. Bacterial stocks were maintained at −80 ◦C as 20%
glycerol suspensions.
4.3. Q22 Treatment
Q22 treatment doses were based on sub-MIC concentrations, unless otherwise indicated [8].
To measure the effects of Q22 treatment on BCC cell morphology and growth, overnight bacterial
cultures were subcultured 1:500 into fresh LB broth, in the absence or presence of Q22, and incubated at
37 ◦C with shaking. LB broth was supplemented with Q22 at the 0 h timepoint. Samples were removed
at selected timepoints as indicated. BCC were additionally grown in the presence of corresponding
volumes of methanol, as a diluent control. A viable count of bacteria in cultures grown in the presence
and absence of Q22 was taken to confirm acceptable use of optical density as a measure of growth.
Scanning electron microscope images of the resulting cells were taken.
4.4. Hydrogen Peroxide (H2O2) Protection Assay
The ability of BCC strains to survive H2O2 exposure was measured, as previously described [10].
Briefly, BCC cultures were grown and shaken at 37 ◦C in LB, supplemented with Q22, diluent control
(methanol), or no supplementation until the late stationary phase. The optical density was determined
and samples were standardised to a concentration of 1 × 108 cfu. Each strain was treated with varying
H2O2 concentrations (0–20 mM) and incubated with shaking at 25 ◦C for 30 min. Control samples
received distilled H2O in place of the H2O2 treatment. Appropriate serial dilutions were plated in
triplicate on LB agar plates. Colonies were counted after 48 h incubation, and percentage survival
calculated by comparison with colony counts obtained from untreated samples.
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4.5. Isolation of Bacterial Whole Cell Lysates (WCLs)
Whole cell lysates (WCLs) were prepared as described, with additional modifications [24]. Briefly,
strains were grown overnight on Brain Heart Infusion (BHI) agar plates or in BHI broth to an optical
density of ~1.8 at 600 nm. Broth grown bacteria were harvested by centrifugation and washed once
with phosphate-buffered saline (PBS), to remove growth media and supplements prior to standardising
to an optical density of 0.2 at 600 nm. Bacterial suspensions were disrupted by sonication with a
Branson 150 sonifier (six cycles, 30 s on, 30 s off) and incubated with 200 µg/mL deoxyribonuclease II
(Dnase II) (Sigma-Aldrich, Saint Louis, MO, USA) at 37 ◦C for 1 h. WCLs were treated with 2 mg/mL
Proteinase K (Sigma-Aldrich) at 60 ◦C for 2 h, boiled for 20 min (inactivating Proteinase K), and stored
at −80 ◦C until required.
4.6. Purification of Lipopolysaccharide (LPS)
Lipopolysaccharide (LPS) was extracted and purified using a modified version of the hot-water
phenol method previously described [25]. Strains were grown to late log phase in nutrient broth
containing 0.5% yeast extract at 37 ◦C. Bacteria were harvested by centrifugation at 1000× g,
re-suspended in a minimal volume distilled water, and freeze-dried. Pellets were re-suspended
in distilled water and sonicated on ice. The resulting sonicated suspension was subjected to Dnase II
digestion (final concentration 200 µg/mL) at 37 ◦C for 2 h, followed by Proteinase K digestion (final
concentration 1 mg/mL) at 60 ◦C for 2 h. After boiling for 20 min, an equal volume was mixed with hot
phenol and incubated at 70 ◦C for 20 min with regular mixing. The suspension was cooled on ice and
centrifuged at 800× g. The water-soluble phase was removed and dialysed against repeated changes
of fresh distilled water for 72 h. Ultracentrifugation at 39,500× g for 6 h at 13 ◦C was undertaken, and
the supernatant was discarded. The resulting pellet was dissolved in a minimal volume of ultrapure
distilled water and freeze-dried. Protein and DNA contamination levels were assessed using a Pierce™
BCA Protein Assay (Thermo Scientific, Waltham, MA, USA) and UV spectrophotometry, respectively,
to ensure an LPS purity level of at least 95% was obtained. LPS samples were analysed by sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and visualised using a Pierce™
Silver Stain kit (Thermo Scientific).
After removal of organic solvents under a vacuum, the lipooligosaccharide (LOS) fraction was
precipitated from concentrated phenol solution with water; the precipitate was washed with aqueous
80% phenol, and then three times with cold acetone and then lyophilized. The LOS fractions were
analyzed by SDS-PAGE on 16% gels, which were stained with silver nitrate
4.7. Isolation of Lipid A
Free lipid A was obtained by hydrolysis of LOS (with 10 mM sodium acetate buffer pH 4.4,
(100 ◦C, 3 h). The solution was extracted three times with chloroform/methanol/H2O (100:100:30
v/v/v) and centrifuged (4 ◦C, 5000× g, 15 min). The organic phase contained the lipid A, and the
water phase contained the core oligosaccharide.
4.8. Matrix Assisted Laser Desorption/Ionization Time of Flight (MALDI-TOF) Mass Spectrometry
MALDI-TOF mass spectra of the intact LOS were recorded in the negative polarity on a Perseptive
(Framingham, MA, USA) Voyager STR equipped with delayed extraction technology. Ions formed by
a pulsed UV laser beam (nitrogen laser, λ = 337 nm) were accelerated by 24 kV.
LOS and lipid A sample preparation: R-type LOS MALDI preparation was performed as recently
reported in detail [26]. MALDI preparation of lipid A was performed as described [27]. Briefly,
samples were dissolved in chloroform/methanol (1:1 v/v), whereas matrix solution was prepared by
dissolving 2,4,6-trihydroxyacetophenone (THAP) in methanol/0.1% trifluoroacetic acid/acetonitrile
(7:2:1). A sample/matrix solution mixture (1:1 v/v) was deposited (1 µL) onto the MALDI plate and
left to dry at room temperature.
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4.9. Purification of Peptidoglycan (PG)
Sacculi were isolated from BCC as described [28], with the following modifications. BCC cells
(800 mL) were grown to an optical density of 0.6 at 600 nm and harvested by centrifugation at 7500× g
for 15 min at 4 ◦C. The cell pellet was re-suspended in 6 mL of ice-cold sterile dH2O. The cell suspension
was added dropwise to 6 mL boiling 8% sodium dodecyl sulphate (SDS) solution. The solution was
boiled for a further 30 min, and the resulting cell suspension pelleted by centrifugation at 130,000× g
for 60 min at 25 ◦C. The pellet was washed repeatedly with dH2O until the supernatant was free of
SDS, as determined by a published assay [29].
4.10. Cell Culture
THP-1 human monocytes [30] were kindly donated by Prof. John Taylor and were maintained at
37 ◦C with 5% CO2 in RPMI-1640 medium (Sigma-Aldrich), supplemented with 10% foetal calf serum
(Sigma-Aldrich), 1% penicillin/streptomycin (Sigma-Aldrich) and 1% L-glutamine (Sigma-Aldrich).
To differentiate the monocytes into macrophage-like cells, 300 µL cells at a concentration of
0.5 × 106 cells/mL was transferred into 24-well tissue culture plates and incubated at 37 ◦C with
5% CO2 for 24 h in the presence of 2.5 ng/mL phorbol myristate acetate (PMA) (Sigma-Aldrich). Prior
to stimulation, the differentiated cells were washed with PBS.
4.11. Stimulation Assays and Cytokine Quantification
Differentiated THP-1 cell lines were stimulated for 6 h with either 12.5 µL/mL bacterial whole
cell lysate, 100 ng/mL LPS, or 100 µg/mL PG as indicated. Culture supernatants were harvested and
assayed for cytokine (TNFα and IL-1β) production using Human DuoSet® ELISA Kits (R&D Systems,
Abingdon-On-Thames, UK). Where indicated, differentiated THP-1 cells were pre-incubated with
CD14 antibody (Monosan, Uden, The Netherlands, Mon1108, final concentration 400 ng/mL) for 1 h
prior to stimulation.
4.12. Zebrafish Model
To determine the toxicity of compound Q22 in vivo, zebrafish embryos staged 30–32 h
post-fertilisation (hpf) were incubated with E3 embryo medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM
CaCl2, 0.33 mM MgSO4) containing increasing concentrations (0, 6.4 µg/mL, 64 µg/mL or 640 µg/mL)
of Q22. A stock solution of 6.4 mg/mL was freshly prepared in E3. Embryos, individually plated in
a 24-well plate (experiment 1: n = 10 per treatment), or in groups of 10–20 embryos in 6-well plates
(experiment 2: n = 40 per treatment; experiment 3: n = 50 per treatment) were incubated at 29 ◦C.
Embryos were observed for five days post-administration, and embryo death was determined by the
absence of a heartbeat.
4.13. Mouse Model
To determine the toxicity of compound Q22 in mammals, 8–10 week old male C57BL/6NCr mice,
20–22 g, from Charles River Laboratories, were housed in filtered cages under specific pathogen-free
conditions, and permitted unlimited access to food and water. Groups of two mice were inoculated
via the intratracheal (IT) route with varying doses (100 mg/kg; 50 mg/kg; 25 mg/kg) of Q22 dissolved
in 60 µL distilled dH2O. Control animals were exposed to 60 µL dH2O as a negative control. For
IT injection, mice were anesthetized by an intraperitoneal injection of Avertin (2,2,2-tribromethanol,
97%) in 0.9% NaCl, administered at a volume of 0.015 mL/g body weight. Mice were placed in a
supine position. The trachea was directly visualised by ventral midline, exposed and intubated with a
sterile, flexible 22 g cannula attached to a 1 mL syringe. After compound administration, moribund
mice (those that could not right themselves after being placed in lateral recumbence) were killed
before termination of the experiments. Remaining groups of mice were monitored twice daily for
the parameters: vocalisation, piloerection, attitude, locomotion, breathing, curiosity, nasal secretion,
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grooming, and dehydration. Mice that lost >25% of their body weight and had evidence of severe
clinical disease, such as scruffy coat, inactivity, loss of appetite, poor locomotion, or painful posture,
were sacrificed before the termination of the experiments with an overdose of carbon dioxide. Mice
were sacrificed by increasing CO2 administration, and lungs were harvested and observed for damage
and inflammation.
4.14. Statistical Methods
Statistical analysis was performed using a paired t-test where appropriate. Differences with p
values of <0.05 were considered statistically significant. For zebrafish survival studies, the data were
plotted using Kaplan–Meier survival curves (Prism GraphPad software version 6.03), and statistical
significance was determined with a log rank test.
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